BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

Philogen immunocytokine for brain cancerUniversity of Zurich and Swiss Federal Institute of Technology Zurich (ETHZ) scientists reported data from the first three patients with grade III/IV glioblastoma in a Phase I/II trial of Philogen S.p.A.’s Fibromun (L19-TNF)...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Dec 7, 2019
Clinical News

Bladder cancer data poise FerGene gene therapy to compete with Keytruda

Less than two weeks after its launch, Ferring’s gene therapy subsidiary has revealed data that suggest its nadofaragene firadenovec could compete with Keytruda in an early form of bladder cancer. The adenovirus serotype 5 vector...
BioCentury | Nov 11, 2019
Clinical News

DxTerity type I interferon biomarker study, launch bolsters lupus patient stratification

Data supporting the commercial launch of DxTerity’s type I interferon gene expression test in systemic lupus erythematosus (SLE) could lower barriers to signal detection in clinical trials by identifying patients who stand to benefit most...
BioCentury | Sep 12, 2019
Financial News

Genenta’s series C marks start of Qianzhan’s European push

...cells (HSCs) engineered to generate an antitumor immune response by selectively expressing interferon α 2 (IFNA2...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

With a spate of new and expanded deals this year, Takeda is not letting its $62 billion dollar takeout of Shire slow its transformation from a traditional small molecule company to a home for edgier,...
BioCentury | Nov 16, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

Publisher’s note: This story originally ran in the Nov. 15, 2018 issue of BioCentury Innovations , a comprehensive source of developments in translational research with knowledgeable perspectives on the key innovations, trends and opportunities in early...
BioCentury | Nov 15, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in Nature Biotechnology last month, the latest advance from the institute centered on an automated, closed system capable of producing clinical-grade...
BioCentury | Jan 4, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Age-related macular degeneration (AMD) Patient sample, cell culture and mouse studies suggest inhibiting cGAS, CASP4, GSDMD, IFNB1, IFNAR1, IRF3 or STAT2 could help treat geographic atrophy. In tissue samples from patients, levels of cGAS,...
BioCentury | Nov 6, 2017
Preclinical News

Team identifies new targets to treat myocardial infarction

In a paper published Monday in Nature Medicine , researchers from Massachusetts General Hospital and colleagues identified the mechanism behind an elevated immune response after myocardial infarction and suggested interferon regulatory factor 3 (IRF3), interferon alpha/beta...
Items per page:
1 - 10 of 651